共查询到20条相似文献,搜索用时 0 毫秒
1.
J F Bergmann M Beaugrand H Labadie J M Bidart C Bohuon 《Clinica chimica acta; international journal of clinical chemistry》1986,155(2):163-165
The presence of Ca 125, an ovarian cancer-associated antigen, was assessed in serum from patients with liver diseases with (n = 26) and without (n = 26) ascites. Abnormal levels of serum CA 125 were observed in all patients with ascites and in 4 patients without ascites (15%). We conclude that CA 125 is a non-specific marker of ascites whatever the origin: ovarian carcinoma, cirrhosis or peritoneal inflammatory process. 相似文献
2.
糖类抗原CA125是卵巢肿瘤细胞表面相关抗原,目前被认为是卵巢癌最敏感的标志物,但还存在不少假阴性:组织多肽特异抗原(tissue polypeptide specific antigern,TPS)是一种反映细胞活性的标志物,TPS的水平与存活的细胞数有相关性。本检测了112例卵巢良、恶性疾病患血清中的CA125、TPS水平,以探讨其在卵巢癌诊断中的意义。 相似文献
3.
4.
ELISA测定血清卵巢癌抗原CA125 总被引:9,自引:0,他引:9
为了能早期诊断卵巢癌,改善其预后,提高其生存率。本文应用ELISA测定了256例血清中CA125抗原,其中包括卵巢癌27例,卵巢癌术后随访12例,其它癌12例,妇科良性肿瘤78例,其它妇科疾病23例及正常对照组104例。结果显示,27例卵巢癌其CA125抗原检出率为93%(25/27),256例血清样品灵敏度测定为82%,特异性为79%,总诊断有效率达80%。结果提示CA125抗原ELISA法测定可能对卵巢癌的早期诊断及疗效观察有一定临床意义。 相似文献
5.
6.
目的 探讨测定血清血管内皮细胞生长因子(VEGF)与肿瘤标记物CA125的水平在卵巢肿瘤诊断中的意义。方法 恶性卵巢肿瘤88例(Ⅰ组)、良性卵巢肿瘤34例(Ⅱ组),正常人24例为对照组,用酶联免疫吸附(ELISA)法及免疫放射分析法(IRMA)分别测定各组术前血清中的VEGF与CA125的水平。结果 Ⅰ组VEGF与CA125水平明显高于Ⅱ组及对照组(P〈0.01);Ⅰ组(Ⅲ~Ⅳ期)患者血清VEGF与CA125水平明显高于Ⅰ组(Ⅰ~Ⅱ期)(P〈0.01);血清VEGF组织类型各组间差异无显著性意义(P〉0.05);而血清CA125组织类型各组间差异有显著性意义(P〈0.01)。结论 血清VEGF、CA125的水平与卵巢肿瘤的恶性行为有关,作为诊断卵巢肿瘤具有较大的价值。 相似文献
7.
H Mochizuki I Sato K Nagoya S Furusako T Yamauchi H Masuko H Sato H Morishita M Yajima H Sasaki 《Journal of clinical laboratory analysis》1992,6(2):84-90
An immunoenzymometric assay (IEMA) for a new CA125-like antigen, CA602, was developed. Five monoclonal antibodies raised against a human ovarian carcinoma cell line could detect their respective antigens in the sera of ovarian carcinoma patients. The antigen levels detected in serum by the various antibodies correlated significantly to each other, and to CA125 levels. The results of epitope analyses and combined IEMAs suggested that the epitopes recognized by these antibodies are not same, but exist on the same antigen which bears the CA125 epitope. A sensitive IEMA was developed with 602-1 and 602-6 antibodies which showed high reactivity to the CA125-like antigen. The antigen defined by these two antibodies was designated as CA602, and serum CA602 levels correlated well with CA125 levels. The CA602 antigen is a CA125-like antigen. Furthermore, the serum CA602 levels did not correlate to CA54/61 levels. The combined assays of CA602 and CA54/61 may increase the detection of ovarian carcinoma. 相似文献
8.
目的探讨癌抗原125(CA125)、癌抗原72-4(CA72-4)联合检测对卵巢肿瘤诊断的价值。方法采用电化学发光法测定54例卵巢癌患者、41例卵巢良性肿瘤患者和40例健康妇女血清中的CA125和CA72-4水平。结果卵巢癌患者血清CA125和CA72-4水平明显高于健康对照组(P<0.05);CA125和CA72-4单项检测诊断卵巢癌的阳性率分别为65.8%和20.3%,均低于联合检测的阳性率(81.5%);联合检测的敏感度(81.5%)和准确性(87.4%)均明显高于单项检测(P<0.05)。结论联合检测CA125和CA72-4对卵巢恶性肿瘤的诊断和鉴别具有重要意义。 相似文献
9.
Robertson DM Cahir N Burger HG Mamers P McCloud PI Pettersson K McGuckin M 《Clinical chemistry》1999,45(5):651-658
BACKGROUND: The reproductive hormone inhibin has been used as a diagnostic marker of ovarian mucinous and granulosa cell cancers. The aims of this study were to develop a new inhibin immunofluorometric assay (alphaC IFMA) to replace an inhibin RIA as a diagnostic marker of these ovarian cancers and to assess whether the alphaC IFMA in combination with CA125, which detects serous cancers, leads to an improved biochemical diagnosis of all ovarian cancers. METHODS: Serum inhibin concentrations were determined in healthy postmenopausal women (n = 165) and women with ovarian cancers (n = 154), using an inhibin RIA and an alphaC IFMA, which detects inhibin forms containing the alphaC subunit as well as the free alphaC subunit. RESULTS: The alphaC IFMA gave a similar or better discrimination of mucinous (90% vs 71%) and granulosa cell (100% vs 100%) cancers compared with the inhibin RIA. Combination of CA125 and alphaC IFMA values by canonical variate analysis or by multiROC analysis showed that the percentage of all ovarian cancers detected was significantly increased compared with either CA125 or alphaC IFMA alone. CONCLUSIONS: The alphaC IFMA shows a similar or better specificity compared with the RIA, but with increased sensitivity. In combination with CA125, the alphaC IFMA provides an effective dual test for the detection of the majority (90%) of ovarian cancers. 相似文献
10.
血清CA125和CA199检测对卵巢癌诊断应用价值的探讨 总被引:7,自引:0,他引:7
目的:通过测定血清中肿瘤标志物 CA125和 CA199水平,探讨其对卵巢癌诊断的应用价值。方法2011年1月至2012年10月确诊的卵巢癌患者61例,卵巢良性疾病患者68例,健康对照者50例,测定血清中 CA125和CA199水平。结果卵巢癌组血清 CA125和 CA199水平均明显高于卵巢良性疾病组和健康对照组,差异有统计学意义(P <0.05);卵巢良性疾病组血清 CA125和 CA199水平与对照组比较,差异无统计学意义(P >0.05);CA125和CA199联合检测的敏感性明显高于 CA125和 CA199单独检测(P <0.05)。结论CA125和 CA199水平进行测定及其联合检测对卵巢癌的诊断、分期和治疗有重要意义。 相似文献
11.
目的 探讨超声检查联合肿瘤标志物在卵巢良、恶性肿瘤鉴别诊断中的价值。方法 回顾性分析经手术病理证实的80例(100个肿块)卵巢良、恶性肿瘤或盆腔其他性质肿块的超声征象,结合肿瘤标记物CA125及CA199的含量,对其进行统计学分析。结果 超声检查对术前卵巢肿瘤的诊断符合率为89.29%,肿瘤标志物CA125、CA199的诊断符合率81.03%,超声检查联合肿瘤标志物CA125、CA199检测的诊断符合率为92.83%,且联合诊断的符合率高于该两种方法单独使用时,差异有统计学意义(P〈0.05)。结论 超声检查卵巢肿瘤二维结构与血流频谱特征,结合检测血清CA125、CA199水平可弥补该两种方法单独诊断时的不足,是鉴别卵巢肿瘤良、恶性的一种良好方法,具有较大的临床应用价值。 相似文献
12.
13.
Aim of this study was to evaluate the significance of serum CA 125 levels in our ovarian cancer follow-up programme for earlier detection of recurrent or progressive disease. 43 out of 133 patients developed tumour progression, whereby 42 (97.7%) showed positive serum CA 125 levels and in 25 patients (58.2%) the increase in tumour marker preceded the first clinical signs by 4 to 36 weeks. The mean lead time was 14.2 weeks. Hence, determination of serum CA 125 should be mandatory in the follow-up investigation of women with epithelial ovarian carcinomas. 相似文献
14.
M. K. Tuxen G. SöLétormos P. Dombernowsky 《Scandinavian journal of clinical and laboratory investigation》2013,73(3):177-188
CA 125 is currently widely applied in the management of patients with ovarian cancer. However, a change in results of CA 125, which should be considered significant, has not been defined. The aim of this study was to investigate the ability of CA 125 to signal progressive ovarian cancer during follow-up after firstline chemotherapy. The study patients were selected retrospectively among 255 patients with stage IC-IV ovarian cancer. The evaluation of the CA 125 information was based on the analytical imprecision, the normal intra-individual biological variation, the sampling interval, and the cut-off value. Additionally, the utility of a new assessment criterion based upon an increment of 2.5 times the baseline CA 125 concentration confirmed by a third measurement was investigated. The efficiency of CA 125 to identify progression and non-progression during follow-up varied between 76.5 and 79.9%, depending on the applied time limit for an acceptable positive lead time. The median lead time for true positive results was 95-99.5 days. Using the new elaborated criterion, the efficiency of CA 125 for identifying progression and non-progression varied between 75.7 and 78.5%, depending on the applied time limit for an acceptable positive lead time. The median lead time for true positive results was 91-95.5 days. CA 125 provided early and reliable information about progressive disease during follow-up. The applied criteria can therefore be recommended in further studies assessing the clinical utility of serological tumor markers in patients with ovarian cancer. 相似文献
15.
Tuxen MK Sölétormos G Dombernowsky P 《Scandinavian journal of clinical and laboratory investigation》2002,62(3):177-188
CA 125 is currently widely applied in the management of patients with ovarian cancer. However, a change in results of CA 125, which should be considered significant, has not been defined. The aim of this study was to investigate the ability of CA 125 to signal progressive ovarian cancer during follow-up after first-line chemotherapy. The study patients were selected retrospectively among 255 patients with stage IC-IV ovarian cancer. The evaluation of the CA 125 information was based on the analytical imprecision, the normal intra-individual biological variation, the sampling interval, and the cut-off value. Additionally, the utility of a new assessment criterion based upon an increment of 2.5 times the baseline CA 125 concentration confirmed by a third measurement was investigated. The efficiency of CA 125 to identify progression and non-progression during follow-up varied between 76.5 and 79.9%, depending on the applied time limit for an acceptable positive lead time. The median lead time for true positive results was 95-99.5 days. Using the new elaborated criterion, the efficiency of CA 125 for identifying progression and non-progression varied between 75.7 and 78.5%, depending on the applied time limit for an acceptable positive lead time. The median lead time for true positive results was 91-95.5 days. CA 125 provided early and reliable information about progressive disease during follow-up. The applied criteria can therefore be recommended in further studies assessing the clinical utility of serological tumor markers in patients with ovarian cancer. 相似文献
16.
O C Boerman C M Thomas M F Segers P Kenemans T L?vgren V R Zurawski H J Haisma L G Poels 《Clinical chemistry》1987,33(12):2191-2194
A time-resolved immunofluorometric assay (IFMA) is described for quantifying the ovarian carcinoma-associated antigenic determinant CA 125 in human serum. Monoclonal antibody to CA 125 is immobilized onto a microtiter well, and the same antibody labeled with a europium chelate is used as a tracer. After the immunoreaction the bound portion of the labeled antibody is quantified by dissociating the Eu3+ in a fluorescence-enhancement solution and measuring its fluorescence with a time-resolved fluorometer. The detection limit of the IFMA is 1.5 arb. units/mL, being about the same as that of a commercially available immunoradiometric assay (IRMA) for CA 125 (1.4 arb. units/mL). The analytical range of the IFMA extends to 2000 arb. units/mL, whereas the range of the IRMA is 500 arb. units/mL. For 29 serum samples from ovarian-cancer patients measured simultaneously in the IFMA and IRMA, orthogonal regression analysis gave the equation CA 125 (IFMA) = 0.9937 CA 125 (IRMA) - 1.211 arb. units/mL (Syx = 6.8681, r = 0.9932). Apparently, the IFMA for CA 125 is a convenient alternative to the IRMA for CA 125 because of short counting times, the use of nonradioactive, stable reagents, and the much-extended measuring range. Additionally, the microtiter format should lend itself to more fully automated procedures in laboratories doing many such analyses. 相似文献
17.
目的研究联合检测血清糖链抗原125(CA125)和血浆D-二聚体水平在卵巢癌诊断中的应用价值。方法分别采用电化学发光法与定量酶联免疫吸附试验(ELISA)检测经病理学确诊的卵巢癌患者75例和卵巢良性肿瘤患者41例的血清CA125及血浆D-二聚体水平,并选择60例健康体检妇女同样检测该两项指标,进行比较。结果卵巢癌组患者的CA125及D-二聚体水平均显著高于卵巢良性肿瘤组及健康对照组(P均<0.01)。单项检测CA125及D-二聚体对卵巢癌诊断的敏感性分别为81.3%及64.0%,特异性分别为82.9%及87.8%,准确性分别为81.9%及72.4%,而两者联合检测对卵巢癌诊断的敏感性为92.0%,特异性为78.0%,准确性为87.1%。联合检测对卵巢癌诊断的敏感性和准确性明显高于单项检测(P均<0.01),虽然特异性有所降低,但无统计学意义(P均>0.05)。结论联合检测CA125及D-二聚体可提高卵巢癌的早期诊断率,有助于准确判断肿瘤的分期及预后。 相似文献
18.
CA125、CA199联合检测对卵巢恶性肿瘤的诊断价值 总被引:5,自引:1,他引:4
目的 探讨血清CA125、CA199联合检测对卵巢肿瘤的临床价值.方法 经病理检查证实,44例为卵巢恶性肿瘤的患者于入院时和手术后3~4个月进行CA125、CA199联合检测,并以62例卵巢良性肿瘤作为对照组.结果 2项指标联合检测较单项检测对诊断卵巢恶性肿瘤的敏感性提高到91.0%,虽特异性有所下降,但总的准确性提高到81.8%,与卵巢良性肿瘤组比较,差异有统计学意义(P<0.05).结论 2项肿瘤标志物联合检测对鉴别卵巢良、恶性肿瘤和判断预后及复发有重大意义. 相似文献
19.
血清CA199、CA125和YKL40联合检测对卵巢癌的诊断价值 总被引:1,自引:0,他引:1
目的探讨血清CA199、CA125和YKL-40联合检测在卵巢癌诊断中的应用价值。方法分别用酶免分析法(EIA)和电化学发光法测定36例卵巢癌、38例卵巢良性肿瘤及40例健康对照妇女血清YKL-40和CA125、CA199水平,YKL-40以健康对照组95%可信区间的上限值为阳性,比较YKL-40和CA125、CA199在三组间、卵巢癌病人不同临床分期阳性率的差异。结果正常对照组血清YKL-40水平的95%可信区间的上限值为76.2ng/mL;卵巢癌患者血清YKL-60水平及阳性率显著高于卵巢良性肿瘤组和对照组(t=3.45,P〈0.01),而卵巢良性肿瘤组和对照组之间差异无统计学意义(t=1.62,P〉0.05)。Ⅲ/Ⅳ期卵巢癌患者血清YKL-40水平显著高于Ⅰ/Ⅱ期患者(t:2.81,P〈0.01)。CA125和CA199联检的阳性率为77.8%,YKL-40与CA125、CA199联合检测的阳性率可达到88.9%。结论YKL-40是一种新的诊断卵巢癌的肿瘤标志物,联合YKL-40,CA199、CA125三项检测可提高对早期卵巢癌诊断的灵敏度,对卵巢癌的诊断有重要临床价值。 相似文献
20.
Eray Yagmur Reinhard Driesch Axel M Gressner Paul Kiefer 《Clinical chemistry and laboratory medicine》2006,44(4):420-422
BACKGROUND: The CA 125 antigen is a large (200-1000 kDa) glycoprotein, present within normal and benign ovarian tissue. We evaluated the analytical performance of the newly available Beckman Coulter OV-Monitor (CA 125 antigen) immunoassay on the Beckman Coulter UniCel DxI 800 analyzer. METHODS: The evaluation was performed according to NCCLS recommendations. RESULTS: The lowest level of CA 125 antigen detectable was 0.374 U/mL. Serial dilution of two pooled CA 125 antigen-rich samples provided a linear response (p<0.0001). For total CV% the following results were obtained: pool sera, 11.7 U/mL (2.70%), 56.3 U/mL (2.41%), 108.43 U/mL (2.31%); and QC sera, 29.4 U/mL (2.57%), 101.1 U/mL (3.26%). Comparison of the OV-Monitor on the UniCel DxI 800 showed linear regression values of r=0.961 vs. the Bayer ADVIA Centaur system and r=0.981 vs. the Abbott AxSYM system. CONCLUSION: Considering the limited number of serum samples analyzed, our data indicate that the Beckman Coulter OV-Monitor immunoassay has excellent analytical performance and shows satisfactory correlation with automated immunoassays on the Abbott AxSYM and Bayer ADVIA Centaur systems. It is easy to perform, accurate and suitable for measurements in routine clinical laboratories. 相似文献